Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Safety of biweekly α1-antitrypsin treatment in the RAPID programme.

Greulich T, Chlumsky J, Wencker M, Vit O, Fries M, Chung T, Shebl A, Vogelmeier C, Chapman KR, McElvaney NG; RAPID Trial Group.

Eur Respir J. 2018 Nov 29;52(5). pii: 1800897. doi: 10.1183/13993003.00897-2018. Print 2018 Nov. No abstract available.

2.

Human Naive and Memory T Cells Display Opposite Migratory Responses to Sphingosine-1 Phosphate.

Drouillard A, Neyra A, Mathieu AL, Marçais A, Wencker M, Marvel J, Belot A, Walzer T.

J Immunol. 2018 Jan 15;200(2):551-557. doi: 10.4049/jimmunol.1701278. Epub 2017 Dec 13.

3.

Comparison of exercise training responses in COPD patients with and without Alpha-1 antitrypsin deficiency.

Jarosch I, Hitzl W, Koczulla AR, Wencker M, Welte T, Gloeckl R, Janciauskiene S, Kenn K.

Respir Med. 2017 Sep;130:98-101. doi: 10.1016/j.rmed.2017.07.009. Epub 2017 Jul 15.

PMID:
29206641
4.

Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).

McElvaney NG, Burdon J, Holmes M, Glanville A, Wark PA, Thompson PJ, Hernandez P, Chlumsky J, Teschler H, Ficker JH, Seersholm N, Altraja A, Mäkitaro R, Chorostowska-Wynimko J, Sanak M, Stoicescu PI, Piitulainen E, Vit O, Wencker M, Tortorici MA, Fries M, Edelman JM, Chapman KR; RAPID Extension Trial Group.

Lancet Respir Med. 2017 Jan;5(1):51-60. doi: 10.1016/S2213-2600(16)30430-1. Epub 2016 Dec 2. Erratum in: Lancet Respir Med. 2017 Feb;5(2):e13.

PMID:
27916480
5.

Immune signatures of protective spleen memory CD8 T cells.

Brinza L, Djebali S, Tomkowiak M, Mafille J, Loiseau C, Jouve PE, de Bernard S, Buffat L, Lina B, Ottmann M, Rosa-Calatrava M, Schicklin S, Bonnefoy N, Lauvau G, Grau M, Wencker M, Arpin C, Walzer T, Leverrier Y, Marvel J.

Sci Rep. 2016 Nov 24;6:37651. doi: 10.1038/srep37651.

6.

Different Training-Induced Skeletal Muscle Adaptations in COPD Patients with and without Alpha-1 Antitrypsin Deficiency.

Jarosch I, Gehlert S, Jacko D, Koczulla RA, Wencker M, Welte T, Bloch W, Janciauskiene S, Kenn K.

Respiration. 2016;92(5):339-347. Epub 2016 Sep 30.

7.

Results from a large targeted screening program for alpha-1-antitrypsin deficiency: 2003 - 2015.

Greulich T, Nell C, Herr C, Vogelmeier C, Kotke V, Wiedmann S, Wencker M, Bals R, Koczulla AR.

Orphanet J Rare Dis. 2016 Jun 10;11(1):75. doi: 10.1186/s13023-016-0453-8.

8.

Epigenetic and transcriptional regulation of γδ T cell differentiation: Programming cells for responses in time and space.

Schmolka N, Wencker M, Hayday AC, Silva-Santos B.

Semin Immunol. 2015 Feb;27(1):19-25. doi: 10.1016/j.smim.2015.01.001. Epub 2015 Feb 25. Review.

PMID:
25726512
9.

Innate-like T cells straddle innate and adaptive immunity by altering antigen-receptor responsiveness.

Wencker M, Turchinovich G, Di Marco Barros R, Deban L, Jandke A, Cope A, Hayday AC.

Nat Immunol. 2014 Jan;15(1):80-7. doi: 10.1038/ni.2773. Epub 2013 Nov 17.

10.

Detection of obstructive sleep apnoea by an electronic nose.

Greulich T, Hattesohl A, Grabisch A, Koepke J, Schmid S, Noeske S, Nell C, Wencker M, Jörres RA, Vogelmeier CF, Köhler U, Koczulla AR.

Eur Respir J. 2013 Jul;42(1):145-55. doi: 10.1183/09031936.00091712. Epub 2012 Oct 25.

11.

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.

Schmid ST, Koepke J, Dresel M, Hattesohl A, Frenzel E, Perez J, Lomas DA, Miranda E, Greulich T, Noeske S, Wencker M, Teschler H, Vogelmeier C, Janciauskiene S, Koczulla AR.

Int J Chron Obstruct Pulmon Dis. 2012;7:687-96. doi: 10.2147/COPD.S34560. Epub 2012 Sep 28.

12.

[Rare diseases in pulmonary medicine and its challenges].

Wencker M, Teschler H, Vogelmeier C, Koczulla R.

Pneumologie. 2012 Jul;66(7):437-41. doi: 10.1055/s-0032-1309876. Epub 2012 Jun 12. Review. German.

13.

HTLV-1 propels thymic human T cell development in "human immune system" Rag2⁻/⁻ gamma c⁻/⁻ mice.

Villaudy J, Wencker M, Gadot N, Gillet NA, Scoazec JY, Gazzolo L, Manz MG, Bangham CR, Dodon MD.

PLoS Pathog. 2011 Sep;7(9):e1002231. doi: 10.1371/journal.ppat.1002231. Epub 2011 Sep 1.

14.

Cutting Edge: Regulator of G protein signaling-1 selectively regulates gut T cell trafficking and colitic potential.

Gibbons DL, Abeler-Dörner L, Raine T, Hwang IY, Jandke A, Wencker M, Deban L, Rudd CE, Irving PM, Kehrl JH, Hayday AC.

J Immunol. 2011 Sep 1;187(5):2067-71. doi: 10.4049/jimmunol.1100833. Epub 2011 Jul 27.

15.

Cutting edge: adaptive versus innate receptor signals selectively control the pool sizes of murine IFN-γ- or IL-17-producing γδ T cells upon infection.

Ribot JC, Chaves-Ferreira M, d'Orey F, Wencker M, Gonçalves-Sousa N, Decalf J, Simas JP, Hayday AC, Silva-Santos B.

J Immunol. 2010 Dec 1;185(11):6421-6425. doi: 10.4049/jimmunol.1002283. Epub 2010 Oct 29.

16.

Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study of augmentation therapy in alpha 1-antitrypsin deficiency.

Parr DG, Dirksen A, Piitulainen E, Deng C, Wencker M, Stockley RA.

Respir Res. 2009 Aug 13;10:75. doi: 10.1186/1465-9921-10-75.

17.

The leukemogenic activity of TaxHTLV-1 during human alphabeta T cell development.

Wencker M, Gazzolo L, Duc Dodon M.

Front Biosci (Schol Ed). 2009 Jun 1;1:194-204. Review.

PMID:
19482695
18.

Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency.

Brand P, Schulte M, Wencker M, Herpich CH, Klein G, Hanna K, Meyer T.

Eur Respir J. 2009 Aug;34(2):354-60. doi: 10.1183/09031936.00118408. Epub 2009 Feb 27.

19.

New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy.

Gross B, Grebe M, Wencker M, Stoller JK, Bjursten LM, Janciauskiene S.

Dermatology. 2009;218(4):370-5. doi: 10.1159/000202982. Epub 2009 Feb 16.

20.

Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.

Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, Stockley RA.

Eur Respir J. 2009 Jun;33(6):1345-53. doi: 10.1183/09031936.00159408. Epub 2009 Feb 5.

21.

Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD.

Schulte M, Osseiran K, Betz R, Wencker M, Brand P, Meyer T, Haidl P.

J Aerosol Med Pulm Drug Deliv. 2008 Dec;21(4):321-8. doi: 10.1089/jamp.2007.0634.

PMID:
18823257
22.

Cross talk between expression of the human T-cell leukemia virus type 1 Tax transactivator and the oncogenic bHLH transcription factor TAL1.

Terme JM, Wencker M, Favre-Bonvin A, Bex F, Gazzolo L, Duc Dodon M, Jalinot P.

J Virol. 2008 Aug;82(16):7913-22. doi: 10.1128/JVI.02414-07. Epub 2008 May 21.

23.

National survey of guideline-compliant COPD management among pneumologists and primary care physicians.

Glaab T, Banik N, Rutschmann OT, Wencker M.

COPD. 2006 Aug;3(3):141-8.

PMID:
17240616
24.

Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease.

Kardos P, Wencker M, Glaab T, Vogelmeier C.

Am J Respir Crit Care Med. 2007 Jan 15;175(2):144-9. Epub 2006 Oct 19.

PMID:
17053207
25.

Human T-cell leukemia virus type 1 Tax protein down-regulates pre-T-cell receptor alpha gene transcription in human immature thymocytes.

Wencker M, Sausse C, Derse D, Gazzolo L, Duc Dodon M.

J Virol. 2007 Jan;81(1):301-8. Epub 2006 Oct 18.

26.

[Guideline-conformity of outpatient COPD management by pneumologists].

Glaab T, Banik N, Trautmann M, Hellmann A, Wencker M.

Pneumologie. 2006 Jul;60(7):395-400. German.

PMID:
16810625
27.

[Guideline conformance for outpatient management of COPD in Germany].

Glaab T, Banik N, Singer C, Wencker M.

Dtsch Med Wochenschr. 2006 May 26;131(21):1203-8. German.

PMID:
16721708
29.

Screening for alpha1-Pi deficiency in patients with lung diseases.

Wencker M, Marx A, Konietzko N, Schaefer B, Campbell EJ.

Eur Respir J. 2002 Aug;20(2):319-24.

30.

Inhalation of [123I]alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency?

Kropp J, Wencker M, Hotze A, Banik N, Hübner GE, Wunderlich G, Ulbrich E, Konietzko N, Biersack HJ.

J Nucl Med. 2001 May;42(5):744-51.

31.

Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor.

Wencker M, Fuhrmann B, Banik N, Konietzko N; Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen.

Chest. 2001 Mar;119(3):737-44.

PMID:
11243951
32.

Blood gases at rest and during exercise in patients with alpha1-Pi deficiency.

Wencker M, Konietzko N.

Respir Med. 2000 Dec;94(12):1177-83.

33.

Screening for alpha1-Pi deficiency in patients with lung diseases.

Wencker M.

Respir Med. 2000 Aug;94 Suppl C:S16-7. No abstract available.

34.

[Augmentation therapy with human alpha 1-protease inhibitor: whom to treat when?].

Wencker M.

Med Klin (Munich). 1999 Mar 15;94(3):137-9. Review. German.

PMID:
10218347
35.

[Long-term therapy of alpha 1-antitrypsin-deficiency-associated pulmonary emphysema with human alpha 1-antitrypsin].

Wencker M, Banik N, Buhl R, Seidel R, Konietzko N.

Pneumologie. 1998 Oct;52(10):545-52. German. Erratum in: Pneumologie 1998 Dec;52(12):VI.

PMID:
9847632
36.

Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor.

Meyer FJ, Wencker M, Teschler H, Steveling H, Sennekamp J, Costabel U, Konietzko N.

Eur Respir J. 1998 Oct;12(4):996-7.

39.

Liver function in patients with pulmonary emphysema due to severe alpha-1-antitrypsin deficiency (Pi ZZ).

von Schönfeld J, Breuer N, Zotz R, Liedmann H, Wencker M, Beste M, Konietzko N, Goebell H.

Digestion. 1996;57(3):165-9.

PMID:
8739089
40.

Transsternal transpericardial operations in the treatment of bronchopleural fistulas after pneumonectomy.

Stamatis G, Martini G, Freitag L, Wencker M, Greschuchna D.

Eur J Cardiothorac Surg. 1996;10(2):83-6.

PMID:
8664010
41.

Omentopexy and muscle transposition: two alternative methods in the treatment of pleural empyema and mediastinitis.

Stamatis G, Freitag L, Wencker M, Greschuchna D.

Thorac Cardiovasc Surg. 1994 Aug;42(4):225-32.

PMID:
7825161
43.

[Anesthesia for cardioversion. A comparison of propofol and etomidate].

Mitterschiffthaler G, Lechleitner P, Hauptlorenz S, Wencker M, Dienstl F.

Cah Anesthesiol. 1990 May-Jun;38(3):159-63. French.

PMID:
2207824
44.

Influence of beta-blockade on ejection fraction, ANP, and cGMP in patients after myocardial infarction.

Hauptlorenz S, Puschendorf B, Wencker M, Dienstl F.

JAMA. 1989 Dec 1;262(21):2996-7. No abstract available.

PMID:
2554003
45.
46.

Rapid decrease in cyclic 3'5'-guanosine monophosphate in the earliest phase of acute myocardial infarction.

Hauptlorenz S, Wencker M, Lechleitner P, Dienstl F, Puschendorf B.

Am J Med. 1989 May;86(5):627-8. No abstract available.

PMID:
2540652
47.

[Myoglobin, L-myosin and cGMP--new laboratory parameters in cardiology].

Puschendorf B, Artner-Dworzak E, Dienstl F, Hauptlorenz S, Vorderwinkler KP, Wencker M.

Z Med Lab Diagn. 1989;30(1):4-5. German. No abstract available.

PMID:
2541573
48.

Atrial natriuretic peptide in AMI.

Lechleitner P, Wencker M, Dienstl F, Hauptlorenz S, Puschendorf B.

Am Heart J. 1988 Jun;115(6):1341-2. No abstract available.

PMID:
2967629
49.

Early decrease in atrial natriuretic peptide in acute myocardial infarction.

Wencker M, Lechleitner P, Dienstl F, Hauptlorenz S, Puschendorf B.

Lancet. 1987 Jun 13;1(8546):1369. No abstract available.

PMID:
2884470

Supplemental Content

Loading ...
Support Center